Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3

NCT05738980 is registered in ClinicalTrials.gov with Beijing Hospital as lead sponsor.

NCT NCT05738980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05738980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
Lead sponsor
Beijing Hospital
Phase
Not applicable
Overall status
Recruiting
Start date
February 1, 2023
Completion date
December 31, 2026
Enrollment
88 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma